AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine

AbbVie has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for atogepant, an oral calcitonin gene-related peptide receptor antagonist, as a prophylaxis of migraine in adults who have four or more migraine days per month. If approved by the European Commission, AbbVie will be the only company to offer a once-daily treatment sp..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 26.
  • textsms

Roche and AbbVie to Compete with New Bispecific Antibodies for Lymphoma Market Share

Roche and AbbVie are set to compete in the lymphoma market with their newly approved bispecific antibodies (BsAbs). Four weeks after AbbVie's Epkinly was approved, the FDA has given its approval for Roche's Genentech's BsAb, Columvi. Both drugs will be available this summer, leading to a head-to-head competition between the two companies. These therapies utilize bispecific antibody design to bin..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 19.
  • textsms

Biden Administration Imposes Penalties on 43 Drugs Due to Price Hikes

The Biden administration is set to impose inflation penalties on 43 Medicare Part B drugs in Q3 of 2023, following the imposition of fines on 27 drugs in March. The Inflation Reduction Act stipulates that pharmaceutical manufacturers must provide justifications for any price increases exceeding the inflation rate, with financial penalties imposed if deemed insufficient. The latest actions are ex..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 10.
  • textsms